新型口服抗凝药物在血栓栓塞性疾病中的应用研究
Chinese Journal of Cardiac Pacing and Electrophysiology（2022）
Abstract
新型口服抗凝药(NOACs)能够弥补华法林的局限性,具有更好的获益/风险比.临床上对于心房颤动、冠心病及静脉血栓栓塞等疾病的抗凝方案也逐步过渡到NOACs,而且存在许多循证医学证据支持.
MoreAI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined